Table 1. Key features comparison of RECIST 1.0 and RECIST 1.1.
| RECIST 1.0 (2000 criteria) | RECIST 1.1 (2009 criteria) | |
|---|---|---|
| Assessment lymph node | Not recommended | Recommended |
| Assessment of tumor burden | Five targets | Ten targets |
| Two per organ | Five per organ | |
| Measuring lymph node | Short axis | Long axis as for other organs |
| Finding of a new lesion | Not specifically defined | Should be unequivocal |
| Patient response to treatment | Initial response to treatment must be confirmed within 4 weeks | Need not be confirmed in randomized trials when the primary end point is disease progression |
| Imaging of non-target lesions | Not specifically addressed | Not necessary at every protocol-specified for declaration of PR or SD |
| Lesions too small to measurement | Not specifically defined | Default value of 5 mm |
| New imaging techniques | No specific recommendation | FDG-PET applied to incorporate as CT scanning assessment |
| Definition of progressive disease | >20% increase in sum of longest diameters form nadir | >20% increase in sum of diameters from nadir, absolute increase of >5 mm |
RECIST: Response Evaluation Criteria In Solid Tumor; PR: partial response; SD: stable disease; FDG-PET: fluorodeoxyglucose–positron emission tomography; CT: computed tomography.